A New Era in Diabetes Management
For millions of people living with diabetes, the daily routine of pricking their fingers multiple times a day to monitor blood sugar levels is more than just an inconvenience—it’s a painful reality that can significantly impact quality of life. But thanks to a groundbreaking innovation from engineers at the Massachusetts Institute of Technology (MIT), this daily ritual may soon be a thing of the past.
MIT researchers have developed a noninvasive imaging method that can accurately measure blood glucose levels by simply shining near-infrared light on the skin. This breakthrough technology, which uses a technique called Raman spectroscopy, promises to eliminate the need for painful finger pricks while providing a more accurate and convenient way to monitor glucose levels.
How the Technology Works
The innovative approach developed at MIT relies on Raman spectroscopy—a technique that reveals the chemical composition of tissues by shining near-infrared or visible light on them. This method allows researchers to detect glucose molecules beneath the skin’s surface without breaking the skin.
“For a long time, the finger stick has been the standard method for measuring blood sugar, but nobody wants to prick their finger every day, multiple times a day. Naturally, many diabetic patients are under-testing their blood glucose levels, which can cause serious complications,” explains Jeon Woong Kang, an MIT research scientist and senior author of the study published in Analytical Chemistry.
The MIT team’s approach represents a significant advancement over previous attempts at noninvasive glucose monitoring. Rather than analyzing the full spectrum of light—which typically contains about 1,000 bands—the researchers focused on just three specific bands that correspond to molecular features. This simplification allows for a smaller, more cost-effective device while maintaining accuracy.
Technical Breakthrough
The key technical breakthrough lies in how the researchers filter out unwanted signals. Typically, glucose signals from beneath the skin are too weak to detect among the myriad of other molecular signals. However, the MIT team found a way to isolate glucose readings by shining near-infrared light onto the skin at a different angle from which they collect the resulting Raman signal.
This approach enabled them to create a device about the size of a shoebox in their initial prototype. Since then, they’ve developed a smaller version about the size of a cellphone, with plans to eventually miniaturize it to watch size. Each measurement takes just over 30 seconds, with readings taken every five minutes during testing.
The Global Diabetes Challenge
The significance of this breakthrough becomes clear when considering the global scale of diabetes. According to the International Diabetes Federation’s Diabetes Atlas, approximately 589 million adults aged 20-79 worldwide were living with diabetes in 2025—that’s roughly one in every nine people. With numbers projected to rise to over 1.3 billion by 2050, the need for improved monitoring solutions is urgent.
“The rising prevalence of diabetes is alarming, with millions of individuals globally affected by the condition, often without their knowledge,” notes a recent study on global diabetes trends. Nearly half of all adults with diabetes are estimated to be undiagnosed, highlighting the need for more accessible monitoring technologies.
Current Monitoring Limitations
Current diabetes management typically involves either traditional finger-prick blood tests or continuous glucose monitors (CGMs) that require a wire to be implanted under the skin. While CGMs have improved diabetes management for many patients, they come with their own set of challenges:
- Skin irritation from the implanted sensor
- Need for sensor replacement every 10-15 days
- Potential for inaccurate readings
- Cost barriers for some patients
- Recent safety concerns, with reports of faulty sensors linked to at least seven deaths
“Continuous glucose monitors have been revolutionary for people with type 1 diabetes, for whom glucose levels are life and death, providing information about how much insulin they need to inject to keep their blood sugar stable,” notes one health reporter who tested CGM technology. “But they’re not without issues.”
Beyond the Technology: Addressing Bias in Medical Devices
An important consideration in developing any medical device is ensuring its effectiveness across diverse populations. The MIT team is actively working to address potential accuracy variations across different skin tones—a critical issue that has plagued other medical technologies.
Research has shown that some medical devices, including pulse oximeters, demonstrate reduced accuracy in patients with darker skin tones. This disparity has serious clinical implications, potentially leading to misdiagnoses and delayed treatments.
The MIT researchers’ focus on skin tone considerations from the development phase demonstrates a growing awareness in the medical technology community about the importance of inclusive design. As noted in a recent npj Digital Medicine study, “Skin tone bias in medical devices is likely due to systemic factors that lead to inadequate validation across diverse skin tones.”
Testing and Future Prospects
In initial clinical testing at the MIT Center for Clinical Translation Research, the device showed accuracy levels similar to those obtained by commercial continuous glucose monitoring sensors. The study involved a healthy volunteer who consumed glucose drinks over a four-hour period, allowing researchers to monitor significant changes in blood glucose concentration.
“With this new approach, we can change the components commonly used in Raman-based devices, and save space, time, and cost,” explains lead author Arianna Bresci, an MIT postdoc. The researchers have since developed a smaller prototype about the size of a cellphone that they’re testing as a wearable monitor in healthy and prediabetic volunteers.
Next year, the team plans to run larger studies working with a local hospital, which will include people with diabetes. The research was funded by the National Institutes of Health, the Korean Technology and Information Promotion Agency for SMEs, and Apollon Inc.
Market Potential
The continuous glucose monitoring market is rapidly expanding, valued at approximately $4.62 billion in 2023 and expected to reach $8.82 billion by 2032, according to market research. Leading companies in this space include Dexcom and Abbott with their FreeStyle Libre systems.
MIT’s noninvasive approach could potentially disrupt this market by offering several advantages:
- Complete elimination of skin penetration
- Reduced cost through simplified technology
- Greater patient comfort and compliance
- Potential for easier integration with smart devices
- Reduced risk of infection or skin irritation
Looking Ahead
While the technology is still in the clinical testing phase, the potential impact on diabetes management is significant. For the hundreds of millions of people worldwide who live with diabetes, the prospect of accurate glucose monitoring without the pain and inconvenience of finger pricks represents a substantial improvement in quality of life.
As Peter So, director of the MIT Laser Biomedical Research Center and co-author of the study, notes, this technology could benefit “almost everyone with diabetes.” The researchers’ attention to device accuracy across different skin tones and their focus on reducing costs through technological simplification suggest a commitment to developing an accessible solution.
The timeline for commercial availability remains uncertain, as larger clinical trials including people with diabetes are still needed. However, given the clear demand for better glucose monitoring solutions and the backing of institutions like MIT and the National Institutes of Health, this technology represents a promising step toward more patient-friendly diabetes management.
For people with diabetes, the end of daily finger pricks may be closer than they think—and it could make a world of difference in their daily lives.
Leave a Reply